RxDoctor Payments Data

Renato Concepcion, MD

Endocrinology, Diabetes & Metabolism · Estero, FLNPI 1962480715

Payments from drug & device makers

$545in general payments, 2019–2025

Across 23 payments — averaging $23.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$172
  • BETA Bionics, Inc.$88
  • Medtronic$64
  • Insulet Corporation$40
  • Radius Health, Inc.$28
  • Dexcom, Inc.$26
  • plus $125 from 7 others

What the payments were for

  • Food & beverage$51194%
  • Education$346%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$545 in reported general payments places this provider in the 20th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$261,604
Medicare patients
816
Services billed
5,665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide561$953,410
MounjaroTirzepatide405$610,911
JardianceEmpagliflozin275$401,694
TrulicityDulaglutide191$294,478
Tresiba Flextouch U-100Insulin Degludec176$169,365
FarxigaDapagliflozin Propanediol122$167,774
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7137$166,681
JanuviaSitagliptin Phosphate116$129,536
ProliaDenosumab68$113,471
Fiasp FlextouchInsulin Aspart (Niacinamide)49$88,869
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog107$80,367
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog71$76,196
Tresiba Flextouch U-200Insulin Degludec69$75,667
Humulin R U-500 KwikpenInsulin Regular, Human32$74,470
Lantus SolostarInsulin Glargine,hum.Rec.Anlog334$56,702

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$172$973,830634 claims
AstraZenecaFarxiga$21$167,774122 claims
AmgenProlia$14$113,47168 claims
Radius Health, Inc.Tymlos$28$27,98411 claims
Sanofi-aventis U.S. LLCLantus$18$3,91023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Estero

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →